Quantcast

FDA deals setback to Silver Spring-based United Therapeutics

United Therapeutics Corp., of Silver Spring, received a setback from the Food and Drug Administration when federal regulators, for the second time, rejected the biopharmaceutical company’s new drug application for oral treprostinil, a treatment for pulmonary arterial hypertension, which is high blood pressure in the arteries that supply the lungs.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

 

[index]
[index]
[i]
[i]
[id, count]
[id, count]
[f.tagName.toLowerCase()]
[f.tagName.toLowerCase()]
[id, validationType, arg1, arg2]
[id, validationType, arg1, arg2]
[field.tagName.toLowerCase()]
[field.tagName.toLowerCase()]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]
[i]